Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of FIbromyalgia)

Table 3 Co-morbidities in CS+/CS- and FM+/FM- patient

	Patients with potential or established fibromyalgia		Patients attending consultation with rheumatologist
	CS+	CS-	FM+	FM-
Number of patients	96	49	20	76
Co-morbidities (%)
Long-term fatigue [95% CI]	76.3 [67.7; 85.0]	68.9 [55.4; 82.4]	85.0 [69.4; 100.0]	74.0 [63.9; 84.0]
Cramp type digestive disorders [95% CI]	54.4 [44.2; 64.5]	52.4 [37.3; 67.5]	79.0 [60.6; 97.3]	48.0 [36.5; 59.4]
Headaches [95% CI]	53.4 [43.0; 63.8]	41.0 [25.6;56.5]	66.7 [44.9; 88.4]	50.0 [38.3; 61.7]
Anxiety 95% CI]	75.8 [67.2; 84.4]	74.4 [61.4; 87.5]	84.2 [67.8; 100.0]	73.7 [63.8; 83.6]
Depression [95% CI]	39.3 [29.2; 49.5]	40.5 [24.7;56.4]	47.4 [24.9; 69.8]	37.1 [25.8;48.5]
Rheumatoid arthritis [95% CI]	7.4 [2.1; 12.6]	19.2 [7.9; 30.4]	15.0 [0.0; 30.7]	5.3 [0.3; 10.4]
Systemic lupus erythematosus [95% CI]	1.1 [0.0; 3.2]	0.0 [0.0; 0.0]	0.0 [0.0; 0.0]	1.4 [0.0; 4.0]

CS+: patients attending consultation with rheumatologist and completing patient questionnaire; CS-: patients completing patient questionnaire without attending consultation with rheumatologist; FM+: = confirmed diagnosis of fibromyalgia by a rheumatologist; FM-: = non-confirmed diagnosis of fibromyalgia by a rheumatologist

ISSN: 1471-2474